Literature DB >> 33486032

Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.

Mengyu Li1, Rachel Yoon Kyung Chang1, Yu Lin1, Sandra Morales2, Elizabeth Kutter3, Hak-Kim Chan4.   

Abstract

Phage cocktail broadens the host range compared with a single phage and minimizes the development of phage-resistant bacteria thereby promoting the long-term usefulness of inhaled phage therapy. In this study, we produced a phage cocktail powder by spray drying three Pseudomonas phages PEV2 (podovirus), PEV1 and PEV20 (both myovirus) with lactose (80 wt%) and leucine (20 wt%) as excipients. Our results showed that the phages remained viable in the spray dried powder, with little to mild titer reduction (ranging from 0.11 to 1.3 logs) against each of their specific bacterial strains. The powder contained spherical particles with a small volume median diameter of 1.9 µm (span 1.5), a moisture content of 3.5 ± 0.2 wt%., and was largely amorphous with some crystalline peaks, which were assigned to the excipient leucine, as shown in the X-ray diffraction pattern. When the powder was dispersed using the low- and high-resistance Osmohalers, the fine particle fraction (FPF, wt. % of particles < 5 µm in the aerosols relative to the loaded dose) values were 45.37 ± 0.27% and 62.69 ± 2.1% at the flow rate of 100 and 60 L/min, respectively. In conclusion, the PEV phage cocktail powder produced was stable, inhalable and efficacious in vitro against various MDR P. aeruginosa strains that cause pulmonary infections. This formulation will broaden the bactericidal spectrum and reduce the emergence of resistance in bacteria compared with single-phage formulations reported previously.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inhalation aerosol; Inhalation drug delivery; Lung infection; Phage combination; Phage therapy; Powder aerosol; Pulmonary infections

Mesh:

Substances:

Year:  2021        PMID: 33486032      PMCID: PMC7904610          DOI: 10.1016/j.ijpharm.2021.120200

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  46 in total

Review 1.  In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation.

Authors:  Stephen P Newman; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2020-06-25       Impact factor: 15.470

Review 2.  The role of particle properties in pharmaceutical powder inhalation formulations.

Authors:  Nora Y K Chew; Hak-Kim Chan
Journal:  J Aerosol Med       Date:  2002

Review 3.  Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.

Authors:  Zhenbo Tong; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Investigation of L-leucine in reducing the moisture-induced deterioration of spray-dried salbutamol sulfate power for inhalation.

Authors:  Liang Li; Sharon Shui Yee Leung; Thomas Gengenbach; Jiaqi Yu; Ge Fiona Gao; Patricia Tang; Qi Tony Zhou; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2017-07-11       Impact factor: 5.875

5.  Viability and electron microscope studies of phages T3 and T7 subjected to freeze-drying, freeze-thawing and aerosolization.

Authors:  C S Cox; W J Harris; J Lee
Journal:  J Gen Microbiol       Date:  1974-03

6.  Mechanism of inactivation in aerosols of bacteriophage T 1 .

Authors:  T Trouwborst; J C de Jong; K C Winkler
Journal:  J Gen Virol       Date:  1972-06       Impact factor: 3.891

7.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

8.  Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.

Authors:  Rachel Yoon Kyung Chang; Ke Chen; Jiping Wang; Martin Wallin; Warwick Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

9.  Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance.

Authors:  Samuel Fischer; Sophie Kittler; Günter Klein; Gerhard Glünder
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

10.  Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization).

Authors:  Maia Merabishvili; Chris Vervaet; Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Jan Mast; Nino Chanishvili; Mario Vaneechoutte
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  6 in total

1.  Characterization of the Bacteriophage BUCT603 and Therapeutic Potential Evaluation Against Drug-Resistant Stenotrophomonas maltophilia in a Mouse Model.

Authors:  Pengjun Han; Wenjing Zhang; Mingfang Pu; Yahao Li; Lihua Song; Xiaoping An; Mengzhe Li; Fei Li; Shuyan Zhang; Huahao Fan; Yigang Tong
Journal:  Front Microbiol       Date:  2022-07-05       Impact factor: 6.064

Review 2.  Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.

Authors:  Hak-Kim Chan; Rachel Yoon Kyung Chang
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-12-30       Impact factor: 3.440

Review 3.  Combating Infectious Diseases with Synthetic Biology.

Authors:  Anooshay Khan; Julian Ostaku; Ebru Aras; Urartu Ozgur Safak Seker
Journal:  ACS Synth Biol       Date:  2022-01-25       Impact factor: 5.110

4.  Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.

Authors:  Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Pharm Res       Date:  2022-09-07       Impact factor: 4.580

Review 5.  Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.

Authors:  Jiaqi Li; Huangliang Zheng; Sharon Shui Yee Leung
Journal:  Pharm Res       Date:  2022-09-19       Impact factor: 4.580

Review 6.  β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects.

Authors:  Karl A Glen; Iain L Lamont
Journal:  Pathogens       Date:  2021-12-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.